Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ELVN-001 |
Synonyms | |
Therapy Description |
ELVN-001 is an ATP-competitive tyrosine kinase inhibitor with selective activity against ABL1, which potentially leads to decreased tumor cell proliferation and antitumor activity (Blood (2022) 140 (Supplement 1): 3095-3096). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ELVN-001 | ELVN 001|ELVN001 | ABL1 Inhibitor 8 | ELVN-001 is an ATP-competitive tyrosine kinase inhibitor with selective activity against ABL1, which potentially leads to decreased tumor cell proliferation and antitumor activity (Blood (2022) 140 (Supplement 1): 3095-3096). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05304377 | Phase I | ELVN-001 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (CML) | Recruiting | USA | FRA | ESP | DEU | CAN | AUS | 1 |